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Abstract: Oxidative stress is considered as a major risk factor that contributes to increased 
lipid peroxidation and declined antioxidants in some degenerative diseases. Glycyrrhizin is 
widely used to cure allergic diseases due to its medicinal properties. In the present study, 
we evaluated the role of glycyrrhizin on lipid peroxidation and antioxidant status in the 
blood and nasal mucosa of allergic rhinitis (AR) mice. Mice were divided into six groups: 
normal control mice, model control (MC) mice, three glycyrrhizin-treated mice groups and 
lycopene-treated mice. Sensitization-associated increase in lipid peroxidation was observed 
in  the  blood  and  nasal  mucosa  of  MC  mice.  Activities  of  antioxidant  enzymes  like 
superoxide  dismutase  (SOD),  catalase  (CAT),  glutathione  peroxidase  (GSH-Px),  total 
antioxidant  capacity  (TAOC)  and  levels  of  glutathione  (GSH)  were  found  to  be 
significantly decreased in  the blood  and nasal  mucosa in  MC mice when compared to 
normal  control  mice.  However,  normalized  lipid  peroxidation  and  antioxidant  defenses 
were reported in the glycyrrhizin-treated and lycopene-treated mice. Moreover, glycyrrhizin 
treatment still enhanced IFN-γ and reduced IL-4 levels in glycyrrhizin-treated mice. These 
findings  demonstrated  that  glycyrrhizin  treatment  enhanced  the  antioxidant  status  and 
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decreased the incidence of free radical-induced lipid peroxidation and improved immunity 
activities in the blood and nasal mucosa of AR mice. 
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1. Introduction 
Allergic  rhinitis  (AR)  affects  both  adolescents  and  younger  children.  AR  may  be  regarded  by 
parents  as  an  irritation  rather  than  as  a  significant  disease  and  is  often  under-diagnosed  and  
under-treated [1]. It is now recognized that AR is made up of more than the classic symptoms of 
sneezing,  rhinorrhea,  and  nasal  obstruction.  AR  is  associated  with  impairments  in  how  patients 
function in day-to-day life at home, at work, and in school [2,3]. Patients may also be bothered by sleep 
disorders, emotional problems, impairment in activities, and social functioning [4]. As allergic AR is 
one of the most frequent diseases encountered in clinical practice, the cost implications to society are 
enormous [5]. 
It has been suggested that oxidative stress is a crucial event in perennial AR [6–9]. Oxidative stress 
has been incriminated as one of several mechanisms that have induced toxic effects in different organs 
due to enhanced production of oxygen free radicals. Glycyrrhizin is a triterpene glycoside. It is a major 
active  constituent  of  licorice  root  (Glycyrrhiza  glabra)  and  has  been  attributed  numerous 
pharmacological effects like anti-inflammatory, anti-viral, anti-tumor, antioxidant and hepatoprotective 
activities [10,11]. Recently, Glycyrrhizin has been reported with many immunomodulatory effects such 
as decreasing the recurrent attack rate of AR and asthma, improving semen quality with treatment [12], 
and modulating allergic inflammation in a murine model for asthma [13]. 
In Japan, glycyrrhizin injections have been used as a therapeutic drug for allergy inflammation since 
1948 and for chronic hepatitis since 1979. Ram et al. [14] demonstrated that Glycyrrhizin significantly 
reduces OVA-induced airway constriction, airway hyperreactivity to methacholine and decreases lung 
inflammation including marked eosinophil infiltration in the mouse model of asthma. In addition, it 
reduces OVA specific IgE levels in serum and Th2 cytokines, IL-4 and IL-5 in BAL fluid. Glycyrrhizin 
has  been  proven  to  have  an  important  potential  in  activating  certain  immune  functions,  such  as 
induction of IFN production, augmentation of NK cell activity and modulation of the growth response 
of lymphocytes through augmentation of IL-2 production [15]. Dai et al. [16] investigated the effects 
of glycyrrhizin on the production of IL-12 and other cytokines, and found that it enhanced both IL-12 
messenger  RNA  accumulation  and  protein  secretion  by  peritoneal  macrophages  in  response  to 
lipopolysaccharide.  
The objective of this study was to determine the antioxidant and immunomodulatory effects of 
Glycyrrhizin in AR mice, which would be beneficial to AR drug therapy. Int. J. Mol. Sci. 2011, 12                       
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2. Materials and methods 
2.1. Preparation of Glycyrrhizin 
The  dried  roots  of  licorice  (600  g)  were  coarsely  grounded  and  extracted  with  boiling  water  
(4 L ×  5) according to Nokhodchi’s mothod [17]. The combined solutions were filtered through a 
sterile 0.20 μm filter and were then boiled for 10 min and set aside at room temperature for 12 h. The 
solution  was  filtered  again  to  eliminate  albuminoid  substances.  After  this  time  the  solution  was 
acidified  gradually  with  sulfuric  acid  (20%  v/v)  step-by-step  until  no  precipitation  occurred.  The 
yellow precipitate (~27 g) was separated by centrifugation and was re-dissolved in a small amount of 
ammonium hydroxide, then its volume was adjusted to 290 mL with distilled water. The precipitation 
procedure with sulfuric acid was repeated. The precipitated material was rinsed several times with 
water in order to neutralize the sulfuric acid. The pasty, acid insoluble precipitate was dried at 40 ° C 
and then ground as fine powder. The obtained sample was analyzed with HPLC and the purity of the 
resultant glycyrrhizin was 93%. 
2.2. Animals 
Male, Kunming mice (28–33 g, body weight, BW), 2–3 month-old, were kept in polyacrylic cages  
(38 cm ×  23 cm ×  10 cm) with ten animals per cage and housed in a room under controlled temperature 
(24–26 ° C), relative humidity (50–60%); with 12 h light–dark cycles. Mice had ad libitum access to 
food in form of dry pellets and water.  
2.3. Allergic Rhinitis Model 
Mice were sensitized by subcutaneous  injection (sc) with  1 mg  antigen ovalbumin mixed with 
80 mg aluminum hydroxide adjuvant in 1 mL saline at footpad, neck, back and groin on the first day. 
Local  challenge  was  performed  everyday  from  day  20  to  day  26  by  dripping  ovalbumin  in 
physiological saline (2 mg mL
−1, 10 μL) into the bilateral nasal cavities using a micropipette. Mice in 
normal control were dripped saline. All procedures were in accordance with China’s National Animal 
Care Guidelines. 
2.4. Animal Grouping and Treatment  
Mice were randomly divided into six groups: the normal control, model, lycopene 20 mg kg
−1 (as 
positive control drug) group, glycyrrhizin 10, 20, 30 mg kg
−1 group. After the sensitization day 14, 
lycopene (30 mg/kg BW) and glycyrrhizin (40 and 80 mg/kg BW) were given orally for 20 days once a 
day. Mice in the normal control and model groups were given saline orally for 20 days once a day. 
2.5. Blood and Tissue Samples  
After 20 days of experiment and overnight fasting, six rats from each group were anesthetized with 
sodium pentobarbital (60 mg/kg body weight) and weighed. Blood was collected from the abdominal 
aorta into tubes containing EDTA, and plasma was prepared by low-speed centrifugation (1000 g for 
20 min, 4 ° C). Nasal mucosa were removed immediately, rinsed with cold saline, weighed and stored Int. J. Mol. Sci. 2011, 12                       
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at  –70  ° C  until  use.  Tissues  were  immediately  homogenized  in  cold  10  mM  Tris-HCl,  pH  7.5  
(1/10  w/v)  with  10  up-and-down  strokes  at  approximately  1200  rev/min  in  a  Teflon-glass 
homogenizer. The homogenates were centrifuged at 4000 ×  g for 10 min to yield a clear supernatant 
fraction that was used for the biochemical analysis. 
2.6. Measurement of OVA-Specific IgE in Plasma 
For OVA-specific IgE titration, plates were coated with OVA (20 μg/mL) and biotin-conjugated rat 
mAb  to  mouse  IgE  (clone  RME-1)  were  used  as  detection  antibodies.  Levels  of  OVA-specific 
antibodies were compared with IgE standards with predetermined concentrations (IgE = 1 μg/mL). The 
concentration of standard serum was arbitrarily assigned as 1 ELISA unit (1 EU). 
2.7. Biochemical Analysis 
The  malonaldehyde  (MDA)  concentrations  were  determined  using  the  method  described  by  
Jain et al. [18] based on TBA reactivity. The GSH concentrations were measured using the method 
described by Beutler et al. [19].  
The catalase (CAT) activity was determined according to the Aebi method [20]. The rate of H2O2 
decomposition was followed by monitoring absorption at 240 nm. One unit of CAT activity is defined 
as the amount of enzyme required to decompose 1 μmoL of hydrogen peroxide in 1 min. The enzyme 
activity was expressed as μmoL H2O2 consumed/min/mg protein. Superoxide dismutase (SOD) activity 
was estimated according to the method of Beauchamp and Fridovich [21]. The developed blue color in 
the reaction was measured at 560 nm. Units of SOD activity were expressed as the amount of enzyme 
required to inhibit the reduction of NBT by 50% and the activity was expressed as U/mg protein. 
Activity of glutathione peroxidase (GSH-Px) was determined according to the method of Lawrence and 
Burk [22]. The assay mixture consisted of 2.0 mL of 75 mM phosphate buffer (pH 7.0), 50 μL of  
60 mM glutathione, 0.1 mL of 30 units/mL glutathione reductase, 0.1 mL of 15 mM EDTA, 0.1 mL of 
3 mM NADPH and the appropriate amount of tissue supernatant to a final volume of 3.0 mL. The 
reaction was started by the addition of 0.1 mL of 7.5 mM H2O2. The rate of change of absorbance 
during the conversion of NADPH to NADP
+ was recorded spectrophotometrically at 340 nm for 3 min. 
GSH-Px activity for tissues was expressed as μmoles of NADPH oxidized to NADP
+ min
−1 mg
−1 
protein. The antioxidant activities (TAOC) in serum and in tissue homogenates were determined with 
enzymatic methods using corresponding diagnostic kits (Nanjing Jiancheng Bioengineering Institute, 
Nanjing, China), according to the instructions of the manufacturer. 
The IFN-γ level was measured by immunoassay. IL-4 level was measured using IL-4 ELISA Kit 
from Diaclone Research, France. 
2.8. Statistical Analyses 
Data obtained were expressed as mean ±  SD (n = 10). The significance of differences between 
means of the TAA determined were examined by one-way ANOVA using the general linear model 
procedure  of  Statistical  Analysis Systems  statistical  software package version 6.11 (SAS Institute, 
Cary, NC, USA). Differences with P < 0.05 were considered statistically significant. Int. J. Mol. Sci. 2011, 12                       
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3. Results 
In untreated AR mice, sneezing and thin nasal discharge was accompanied by excessive scratching. 
In glycyrrhizin-treated groups (20 and 30 mg/kg BW), abnormal symptoms were not found. However, 
in  AR  mice  treated  with  glycyrrhizin  (10  mg/kg  BW),  sneezing  and  thin  nasal  discharge  was 
accompanied by slightly scratching. In the lycopene-treated group, sneezing and thin nasal discharge 
was accompanied by slightly scratching. During the experiment, there was no serious or purulent nasal 
discharge at  all.  None of experimental animals developed secondary infections or were treated by 
additional drugs, such as antibiotics. In the medicine-treated groups, two mice died. 
As can be seen in Table 1, body weights were significantly higher (P < 0.05) in the untreated AR 
mice than the normal control mice (P < 0.01). Mice having received an oral administration of lycopene 
and glycyrrhizin had lower body weight than that of the untreated AR mice. However, a statistical 
difference  was  not  found.  In  addition,  mice  having  received  an  oral  administration  of  lycopene  
(20 mg kg
−1 BW) had slightly (P > 0.01) lower body weight than that of mice receiving an equivalent 
dose of glycyrrhizin. 
Table 1. Body weight in different groups. 
Group  Body weight (g) 
NC  38.47 ±  1.17 
MC  36.88 ±  2.13 a 
lycopene 20 mg kg
−1  37.32 ±  1.65  
glycyrrhizin 10 mg kg
−1  37.52 ±  1.93  
glycyrrhizin 20 mg kg
−1  37.83 ±  2.31  
glycyrrhizin 30 mg kg
−1  37.94 ±  2.51  
aP < 0.01, compared with NC group. 
NC: normal control; MC: model control. 
As can be seen from Table 2, OVA specific IgE levels were significantly higher (P < 0.05) in 
untreated  AR  mice  than  normal  control  mice  (P  <  0.01).  Oral  administration  of  glycyrrhizin 
significantly and in a dose-dependent manner (P < 0.05; P < 0.01) reduced OVA specific IgE levels in 
untreated  AR  mice  compared  to  normal  control  mice.  Oral  administration  of  lycopene  slightly  
(P > 0.05) reduced OVA specific IgE levels in untreated AR mice compared to normal control.  
Table 2. OVA specific IgE levels in different groups. 
Group  OVA specific IgE 
NC  1.35 ±  0.12 
MC  4.59 ±  0.36 
a 
lycopene 20 mg kg
−1  4.03 ±  0.44  
glycyrrhizin 10 mg kg
−1  3.49 ±  0.35 
a 
glycyrrhizin 20 mg kg
−1  2.82 ±  0.17 
b 
glycyrrhizin 30 mg kg
−1  1.98 ±  0.13 
b 
aP < 0.01, compared with NC group; 
aP < 0.01, 
bP < 0.01, compared with MC group. Int. J. Mol. Sci. 2011, 12                       
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As can be seen from Table 3, while blood and nasal mucosa MDA contents were significantly 
higher  in  untreated  AR  mice  than  normal  control  mice  (P  <  0.01),  they  decreased  significantly  
(P < 0.05, P < 0.01) in medicine-treated (lycopene and glycyrrhizin) groups when compared to untreated 
AR mice (P < 0.01). Mice having received an oral administration of lycopene (20 mg kg
−1 BW) had 
markedly (P < 0.01) lower concentrations of MDA than that of mice receiving an equivalent dose of 
glycyrrhizin.  
Table 3. Blood and nasal mucosa MDA levels in different groups. 
Group  blood  nasal mucosa 
MDA (nmol/mg protein)  MDA (nmol/mg protein) 
NC  5.34 ±  0.09  4.93 ±  0.09 
MC  7.85 ±  0.08 
b  8.35 ±  0.13 
b 
lycopene 20 mg kg
−1  5.12 ±  0.09 
d  5.18 ±  0.03 
d 
glycyrrhizin 10 mg kg
−1  7.15 ±  0.06 
c  6.76 ±  0.14 
d 
glycyrrhizin 20 mg kg
−1  6.98 ±  0.07 
d   6.01 ±  0.12 
d  
glycyrrhizin 30 mg kg
−1  6.77 ±  0.08 
d  5.34 ±  0.12 
d 
bP < 0.01, compared with NC group; 
cP < 0.01, 
dP < 0.01, compared with MC group. 
Table 4 shows the blood and nasal mucosa GSH levels at the end of the experiment. After 12 days 
of treatment, the GSH concentrations of untreated AR mice showed a significant (P < 0.01) decrease 
compared with the normal control mice. However, an increase of GSH concentration of mice in the 
medicine-treated  (lycopene  and  glycyrrhizin)  groups  was  observed  (P  <  0.01).  There  was  a  
dose-dependent relationship between GSH concentration and glycyrrhizin consumption. Mice having 
received an oral administration of lycopene (20 mg kg
−1 BW) had higher concentrations of GSH than 
that of mice receiving an equivalent dose of glycyrrhizin.  
Table 4. Blood and nasal mucosa GSH levels in different groups. 
Group  blood  nasal mucosa 
GSH (nmol/mg protein)  GSH (nmol/mg protein) 
NC  8.04 ±  0.32  5.43 ±  0.11 
MC  3.32 ±  0.11 
b  2.97 ±  0.09 
b 
lycopene 20 mg kg
−1  7.57 ±  0.12 
d  6.03 ±  0.11 
d 
glycyrrhizin 10 mg kg
−1  5.76 ±  0.15 
d  3.89 ±  0.08 
d 
glycyrrhizin 20 mg kg
−1  6.43 ±  0.18 
d  4.38 ±  0.09 
d 
glycyrrhizin 30 mg kg
−1  7.71 ±  0.24 
d  5.96 ±  0.12 
d 
bP < 0.01, compared with NC group; 
dP < 0.01, compared with MC group. 
The SOD, CAT, GSH-Px and TAOC activities significantly (P < 0.01) decreased in blood and nasal 
mucosa of untreated AR mice compared to normal control mice. The decreases were significantly 
restored (P < 0.01) in the mice supplemented with lycopene and glycyrrhizin (Tables 5 and 6). There 
was  a  dose-dependent  relationship  between  antioxidant  enzymes’  activities  and  glycyrrhizin 
consumption. Mice having received an oral administration of lycopene (20 mg kg
−1 BW) had higher 
antioxidant enzyme activities than that of mice receiving an equivalent dose of glycyrrhizin.  Int. J. Mol. Sci. 2011, 12                       
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Table 7 shows the nasal mucosa IFN-γ, IL-4 levels and IFN-γ/IL-4 at the end of the experiment. 
After 12 days of treatment, the IFN-γ, IL-4 concentrations of untreated AR mice showed a significant 
(P < 0.01) decrease and increase compared with the normal control mice. Subsequently, IFN-γ/IL-4 
markedly  decreased.  However,  lycopene  and  glycyrrhizin  administration  significantly  (P  <  0.01) 
increased  nasal  mucosa  IFN-γ  and  reduced  IL-4  concentration  of  mice  in  the  medicine-treated 
(lycopene and glycyrrhizin) groups. Subsequently, IFN-γ/IL-4 markedly increased. There was a dose-
dependent  relationship  between  IFN-γ,  IL-4  levels  and  glycyrrhizin  consumption.  Mice  having 
received an oral administration of lycopene (20 mg kg
−1 BW) had lower IFN-γ and higher IL-4 levels 
than those of mice receiving an equivalent dose of glycyrrhizin. 
Table 5. Blood SOD, CAT, GSH-Px and TAOC activities in different groups. 
Group  SOD  
(U/mg protein) 
CAT  
(U/mg protein) 
GSH-Px  
(U/ mg protein) 
TAOC  
(U/mg protein) 
NC  198.4 ±  4.98  23.09 ±  0.98  15.02 ±  0.76  10.87 ±  0.35 
MC  154.2 ±  7.34 
b  17.56 ±  0.89 
b  9.03 ±  0.09 
b  7.45 ±  0.42 
b 
lycopene 20 mg kg
−1  253.6 ±  9.04 
d  23.98 ±  0.16 
d  18.85 ±  0.13 
d  12.09 ±  0.35 
d 
glycyrrhizin 10 mg kg
−1  160.4 ±  5.09 
d  19.85 ±  0.95 
d  11.46 ±  0.72 
d  8.98 ±  0.29 
d 
glycyrrhizin 20 mg kg
−1  169.8 ±  4.99 
d  21.12 ±  1.08 
d  12.54 ±  0.58 
d  9.34 ±  0.27 
d 
glycyrrhizin 30 mg kg
−1  175.9 ±  5.07 
d  22.11 ±  0.91 
d  13.27 ±  0.29 
d  10.32 ±  0.16 
d 
bP < 0.01, compared with NC group; 
dP < 0.01, compared with MC group. 
Table 6. Nasal mucosa SOD, CAT, GSH-Px and TAOC activities in different groups. 
Group  SOD  
(U/mg protein) 
CAT  
(U/mg protein) 
GSH-Px  
(U/mg protein) 
TAOC  
(U/mg protein) 
NC  231.5 ±  7.7  24.65 ±  0.67  19.05 ±  0.57  11.05 ±  0.37 
MC  165.3 ±  4.9 
b  13.47 ±  0.54 
b  11.87 ±  0.39 
b  5.89 ±  0.04 
b 
lycopene 20 mg kg
−1  227.4 ±  8.2 
d  22.13 ±  1.09 
d  21.03 ±  0.27 
d  11.32 ±  0.09 
d 
glycyrrhizin 10 mg kg
−1  179.4 ±  5.1 
d  16.84 ±  0.78 
d  14.07 ±  0.13 
d  7.07 ±  0.08 
d 
glycyrrhizin 20 mg kg
−1  195.6 ±  8.9 
d  18.03 ±  0.67 
d  16.48 ±  0.24 
d  8.25 ±  0.07 
d 
glycyrrhizin 30 mg kg
−1  218.8 ±  6.2 
d  19.36 ±  0.47 
d  18.04 ±  0.65 
d  9.03 ±  0.08 
d 
bP < 0.01, compared with NC group; 
dP < 0.01, compared with MC group. 
Table 7. Nasal mucosa IFN-γ, IL-4 levels and IFN-γ/IL-4 in different groups. 
Group  IFN-γ (pg/mg)  IL-4 (pg/mg)  IFN-γ/IL-4 
NC  74.38 ±  2.82  56.29 ±  1.23  1.33 ±  0.09 
MC  68.56 ±  1.73 
b  61.35 ±  1.95 
b  1.07 ±  0.05 
b 
lycopene 20 mg kg
−1  71.36 ±  1.71 
d  59.09 ±  1.06 
d  1.19 ±  0.04 
d 
glycyrrhizin 10 mg kg
−1  70.21 ±  1.47 
d  59.28 ±  1.11 
d  1.18 ±  0.07 
d 
glycyrrhizin 20 mg kg
−1  72.82 ±  2.02 
d  58.32 ±  1.79 
d  1.25 ±  0.06 
d 
glycyrrhizin 30 mg kg
−1  73.99 ±  2.36 
d  56.93 ±  1.37 
d  1.31 ±  0.05 
d 
bP < 0.01, compared with NC group; 
dP < 0.01, compared with MC group. Int. J. Mol. Sci. 2011, 12                       
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4. Discussion 
Oxidative stress plays an important role in allergic disorders and increased levels of oxidants are 
considered as markers of the inflammatory process. Overproduction of oxygen free radicals, while the 
natural  scavenging  mechanisms  are  weakened,  is  a  process  that  is  implicated  in  cell  damage  and 
multiorgan failure [23]. 
In the present study, we found a significantly lower plasma and nasal mucosa total antioxidant status 
in untreated AR mice. Our observation is supported by earlier reports [24]. Glycyrrhizin is used as 
natural sweetener, anti-ulcerative, and anti-inflammatory preparations [25]. Glycyrrhizin is reported to 
exhibit  antiviral  [26],  anti-HIV  [27,28],  antitumor  [29],  antioxidant  [30]  and  immunomodulatory 
activity [27,29]. Synthesis of glycyrrhizin or its analogues has not been proven to be commercially 
feasible [31]. Studies conducted earlier with glycyrrhizin have shown it to counteract CCl4-induced 
hepatotoxicity  with  the  anti-oxidative  potential  [32].  As  a  major  component  of  licorice  root, 
glycyrrhizin consists of glycyrrhetic acid and two molecules of glucuronic acid. It has been shown that 
glycyrrhizin and its biologically transformed metabolite called 18 β-glycyrrhetinic acid, an aglycon 
component of glycyrrhizin, inhibit the passive cutaneous anaphylaxis and skin contact inflammation in 
mice models of contact hypersensitivity [33]. Lycopene is the red pigment in tomatoes and is known  
as a potent antioxidant [34,35]. Dietary intake of tomatoes and tomato products is reportedly associated 
with  a  decreased  risk  of  cardiovascular  disease  and  several  types  of  cancer,  especially  prostate  
cancer [36–38]. 
The treatment of animals with glycyrrhizin significantly ameliorated GSH content with concomitant 
decrease in MDA. It can be suggested that glycyrrhizin has established antioxidant properties that 
might have counteracted the oxidative injury in AR mice by effectively scavenging and blocking the 
conjugation of reactive intermediates to GSH, as evident from ameliorated GSH content and decreased 
MDA formation in a dose dependent manner. Concomitant decreases were observed in GPx, CAT, 
TAOC and SOD activities in AR mice. Treatment with glycyrrhizin and Lycopene led to significant 
increases in the above mentioned enzymes. Our results indicated that the use of glycyrrhizin in the 
therapy of AR allows oxidative stress to be abolished or reduced by correcting the antioxidant system. 
It is evident from the results that glycyrrhizin induces a variety of enzymes; phase II enzymes involved 
in the detoxification and excretion of carcinogenic or toxic substances and other antioxidant enzymes 
responsible for maintaining a balanced state between free radicals/oxidants and the antioxidants within 
the  cellular  environment.  In  addition,  blood  IFN-γ  level  was  markedly  reduced,  while  IL-4  level 
increased in AR mice. Treatment with glycyrrhizin led to a significant increase of IFN-γ level and 
decrease of IL-4 level in medicine-treated mice. IFN-γ, or type II interferon, is a cytokine that is critical 
for innate and adaptive immunity against viral  and intracellular bacterial infections and for tumor 
control. Aberrant IFN-γ expression is associated with a number of autoinflammatory and autoimmune 
diseases [39]. Interleukin-4, abbreviated IL-4, is a cytokine that induces differentiation of naive helper 
T cells (Th0 cells) to Th2 cells. Upon activation by IL-4, Th2 cells subsequently produce additional  
IL-4. It has many biological roles, including the stimulation of activated B-cell and T-cell proliferation, 
and the differentiation of CD4
+ T-cells into Th2 cells [40]. Treatment with glycyrrhizin may induce 
Th1  cells  differentiation,  maturation  and  IFN-γ  production.  In  addition,  it  reduced  lgE  synthesis 
possibly  by  inhibiting  Th1  cells  differentiation,  maturation  and  IL-4  production,  subsequently Int. J. Mol. Sci. 2011, 12                       
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prevented  AR  development.  Likewise,  Lycopene  increased  IFN-γ  level  and  decrease  IL-4 level  in 
medicine-treated mice. Lee et al [41] reported that Lycopene reduced the increased levels of IL-4 in 
OVA-challenged mice. This is in agreement with our results. Lycopene reduced the increased levels of 
GATA3 mRNA in OVA-challenged mice. This suggests that lycopene treatment is a novel, selective 
way to simultaneously suppress GATA-3 and increase T-bet expression in asthmatic reactions in vivo 
[42]. In the human body, glycyrrhizin is hydrolysed to glycyrrhetinic acid, which has a triterpenoid 
structure that is  similar  to  the hormones  of the adrenal  cortex. Recently,  research has shown that 
glycyrrhetinic acid inhibits the enzyme 11-beta-hydroxy steroid dehydrogenase, which is responsible 
for converting cortisol—the active form—into its inactive metabolites. Thus, inhibition of the enzyme 
by  glycyrrhetinic  acid  significantly  increases  the  levels  of  cortisol  and  also  stimulation  of  the 
glucocorticoid receptors. This in turn potentiates the action of hydrocortisone, the main glucocorticoid 
secreted by the adrenal  cortex. Hydrocortisone is  associated with, and accounts for glyrrhizin and 
glycyrrhetinic  acid’s  antiinflammatory,  anti-allergic  and  anti-arthritic  effects,  and  also  its  role  in 
stimulating  the  adrenal  cortex  after  steroid  therapy  [43–45].  Fangzhibiyan  tablets  (produced  by 
Guangxi  Yunling  Pharmaceutical  Co.  Ltd)  can  effectively  alleviate  patients  suffering  from  AR. 
Glycyrrhizin  is  an  important  functional  component  in  the  tablet  [46].  In  short,  treatment  with 
glycyrrhizin may be considered as a therapeutic option in AR patients by, for example, increasing the 
antioxidant  capacities,  counteracting  the  oxidative  injury  and/or  improving  the  control  of  the 
inadequate inflammatory and immune response. 
5. Conclusion 
As far as we know this is the first work that shows antioxidant and immunity effects of glycyrrhizin 
in AR mice. In conclusion, in AR mice glycyrrhizin consumption decreases blood and nasal mucosa 
antioxidant enzymes activities, lipid peroxidation and GSH levels, and enhances IFN-γ, reduces IL-4 
levels, thus protecting the nasal mucosa oxidative injury and improving immunity activity in AR mice. 
The  inhibition  effects  of  the  glycyrrhizin  against  nasal  mucosa  oxidative  injury  increase  with 
increasing  concentrations.  Further  studies  are  required  to  determine the causes behind  the distinct 
effects of glycyrrhizin. 
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